Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

eIF4B phosphorylation by pim kinases plays a critical role in cellular transformation by Abl oncogenes.

Yang J, Wang J, Chen K, Guo G, Xi R, Rothman PB, Whitten D, Zhang L, Huang S, Chen JL.

Cancer Res. 2013 Aug 1;73(15):4898-908. doi: 10.1158/0008-5472.CAN-12-4277. Epub 2013 Jun 7.

2.

eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.

Chen K, Yang J, Li J, Wang X, Chen Y, Huang S, Chen JL.

Oncotarget. 2016 Mar 1;7(9):10073-89. doi: 10.18632/oncotarget.7164.

3.

Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.

Adam M, Pogacic V, Bendit M, Chappuis R, Nawijn MC, Duyster J, Fox CJ, Thompson CB, Cools J, Schwaller J.

Cancer Res. 2006 Apr 1;66(7):3828-35.

4.

The over-expression of Pim-2 promote the tumorigenesis of prostatic carcinoma through phosphorylating eIF4B.

Ren K, Gou X, Xiao M, Wang M, Liu C, Tang Z, He W.

Prostate. 2013 Sep;73(13):1462-9. doi: 10.1002/pros.22693. Epub 2013 Jun 27.

PMID:
23813671
5.

Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene.

Chen JL, Limnander A, Rothman PB.

Blood. 2008 Feb 1;111(3):1677-85. Epub 2007 Nov 27.

6.

AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B.

van Gorp AG, van der Vos KE, Brenkman AB, Bremer A, van den Broek N, Zwartkruis F, Hershey JW, Burgering BM, Calkhoven CF, Coffer PJ.

Oncogene. 2009 Jan 8;28(1):95-106. doi: 10.1038/onc.2008.367. Epub 2008 Oct 6.

PMID:
18836482
7.

Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells.

Guo G, Qiu X, Wang S, Chen Y, Rothman PB, Wang Z, Chen Y, Wang G, Chen JL.

Oncogene. 2010 Jul 1;29(26):3845-53. doi: 10.1038/onc.2010.149. Epub 2010 May 3.

PMID:
20440266
8.

Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis.

Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA, Skorski T.

Blood. 2002 Jun 15;99(12):4531-9.

9.

Pim kinase substrate identification and specificity.

Peng C, Knebel A, Morrice NA, Li X, Barringer K, Li J, Jakes S, Werneburg B, Wang L.

J Biochem. 2007 Mar;141(3):353-62. Epub 2007 Jan 18.

PMID:
17234686
11.

Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.

Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.

Oncogene. 2008 Aug 7;27(34):4678-89. doi: 10.1038/onc.2008.107. Epub 2008 Apr 21.

PMID:
18427551
12.

Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration.

Grundler R, Brault L, Gasser C, Bullock AN, Dechow T, Woetzel S, Pogacic V, Villa A, Ehret S, Berridge G, Spoo A, Dierks C, Biondi A, Knapp S, Duyster J, Schwaller J.

J Exp Med. 2009 Aug 31;206(9):1957-70. doi: 10.1084/jem.20082074. Epub 2009 Aug 17.

13.

Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.

Mandanas RA, Leibowitz DS, Gharehbaghi K, Tauchi T, Burgess GS, Miyazawa K, Jayaram HN, Boswell HS.

Blood. 1993 Sep 15;82(6):1838-47.

14.

Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma.

Weirauch U, Beckmann N, Thomas M, Gr├╝nweller A, Huber K, Bracher F, Hartmann RK, Aigner A.

Neoplasia. 2013 Jul;15(7):783-94.

15.

A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.

Lin YW, Beharry ZM, Hill EG, Song JH, Wang W, Xia Z, Zhang Z, Aplan PD, Aster JC, Smith CD, Kraft AS.

Blood. 2010 Jan 28;115(4):824-33. doi: 10.1182/blood-2009-07-233445. Epub 2009 Nov 23.

16.

The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling.

Cen B, Xiong Y, Song JH, Mahajan S, DuPont R, McEachern K, DeAngelo DJ, Cortes JE, Minden MD, Ebens A, Mims A, LaRue AC, Kraft AS.

Mol Cell Biol. 2014 Jul;34(13):2517-32. doi: 10.1128/MCB.00147-14. Epub 2014 Apr 28.

17.

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ.

J Natl Cancer Inst. 2008 Jul 2;100(13):926-39. doi: 10.1093/jnci/djn188. Epub 2008 Jun 24.

18.

The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity.

Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, Hershey JW, Blenis J, Pende M, Sonenberg N.

EMBO J. 2006 Jun 21;25(12):2781-91. Epub 2006 Jun 8.

19.

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.

Zhou LL, Zhao Y, Ringrose A, DeGeer D, Kennah E, Lin AE, Sheng G, Li XJ, Turhan A, Jiang X.

J Exp Med. 2008 Oct 27;205(11):2657-71. doi: 10.1084/jem.20072316. Epub 2008 Oct 20.

20.

Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival.

Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB.

Blood. 2005 Jun 1;105(11):4477-83. Epub 2005 Feb 10.

Supplemental Content

Support Center